Physician profile
Gary Smith
NPI 1568454791
$3,078.08
in general payments reported to CMS, 2019-2025
22 companies · $41.85 in 2025
The $41.85 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $1,264 · 2021: $230 · 2022: $41.36 · 2023: $118 · 2024: $61.66 · 2025: $41.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $671.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.51 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $376.89 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $278.86 | 2019-2021 | |
| Grifols USA, LLC | $213.14 | 2019-2020 | |
| Pfizer INC. | $158.43 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $153.70 | 2021 | |
| Electromed, INC. | $150.82 | 2019-2023 | Smartvest |
| Genentech USA, INC. | $117.80 | 2019-2020 | |
| Mylan Specialty L.P. | $69.67 | 2019-2020 | |
| Insmed, INC. | $69.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.50 | 2020 | |
| Sanofi-Aventis U.S. LLC | $49.15 | 2020 | |
| Allergan, INC. | $40.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $33.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.18 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.43 | 2020 | |
| Blueprint Medicines Corporation | $20.51 | 2020 | |
| Mallinckrodt Enterprises LLC | $17.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.